PLAINSBORO, New Jersey, and BAGSVÆRD, Denmark, October 29, 2026
Novo Nordisk has announced that it will present new clinical and real-world research findings across 26 scientific abstracts at ObesityWeek® 2026, scheduled to take place from November 14–17 in Washington, D.C., United States. The presentations will highlight developments across the company’s obesity treatment portfolio, including its investigational combination therapy CagriSema, oral and injectable Wegovy® (semaglutide), and investigational semaglutide injection for younger children living with obesity. The research programme will explore weight reduction, treatment preferences, quality of life, food-related psychological experiences and real-world treatment outcomes. The announcement represents an important step in Novo Nordisk’s ongoing efforts to expand scientific understanding of obesity and develop treatment strategies for patients across different age groups and clinical settings. The 26 abstracts will include findings from clinical trials, post-hoc analyses and real-world evidence studies, providing insights into the potential benefits and treatment experiences associated with different obesity management approaches.
CagriSema Clinical Programme Highlights New Research
One of the major areas of focus at ObesityWeek 2026 will be CagriSema, Novo Nordisk’s investigational combination treatment containing cagrilintide and semaglutide. The company will present primary results from the Phase 3 REDEFINE 9 study, which evaluated lower doses of CagriSema in adults with overweight or obesity. The programme will also feature additional post-hoc analyses from the pivotal REDEFINE 1 trial. These analyses will investigate changes in weight-related quality of life, physical functioning and psychosocial well-being, alongside weight-loss responses across different patient populations. Other research will examine early treatment responses, weight-loss trajectories and the potential impact of CagriSema on cardiovascular disease prevention in people with overweight or obesity. The studies are intended to provide a broader understanding of how treatment responses may vary according to baseline body mass index, obesity-related complications and individual patient characteristics. The REDEFINE programme represents an important component of Novo Nordisk’s clinical development strategy for next-generation obesity treatments. However, CagriSema remains investigational and has not received regulatory approval in the United States or elsewhere.
Wegovy Research Explores Real-World Weight Loss and Food Noise
Another major component of the scientific programme will focus on Wegovy (semaglutide), including oral tablets and injectable formulations. Novo Nordisk will present findings from real-world studies examining treatment experiences among adults with overweight or obesity, including older patients and individuals receiving care through telehealth platforms. The OPTIC study will investigate differences in obesity medication preferences among adults aged 65 years and older compared with younger adults. Additional research from the OCTANE study will examine real-world outcomes among patients initiating oral semaglutide through the Ro telehealth platform, including weight changes, patient-reported outcomes and improvements in food-related experiences after three months. The SIGNAL analysis will evaluate changes in food noise and body weight among treatment-naive adults initiating Wegovy injections, with follow-up extending to six months. Food noise refers to persistent thoughts and preoccupation with food that may influence eating behaviours. Researchers will also present findings from the SWEEP study, which evaluates weight-related outcomes and patient experiences among individuals beginning Wegovy tablets through Novo Nordisk’s digital patient support programme. These studies will provide additional information about treatment experiences outside traditional clinical trial settings.
Advertisement
STEP Young Study Expands Childhood Obesity Research
Novo Nordisk will also present full findings from the STEP Young clinical trial, which evaluated once-weekly investigational semaglutide injections in children aged 6 to under 12 years living with obesity. The study investigated semaglutide alongside lifestyle interventions, including a reduced-calorie diet and increased physical activity. Childhood obesity is a complex chronic condition associated with several long-term health risks, including metabolic disorders, cardiovascular complications and psychological challenges. Research into age-appropriate treatment approaches is therefore an important area of clinical development. The STEP Young findings will expand the available evidence regarding semaglutide’s potential role in younger paediatric populations. The full study results are scheduled for presentation at ObesityWeek 2026 and simultaneous publication. Investigational semaglutide injection is not approved in the United States for children younger than 12 years, and further regulatory evaluation would be required before any potential paediatric indication could be authorized.
The announcement of 26 abstracts demonstrates Novo Nordisk’s continued investment in obesity research, clinical innovation and real-world evidence generation. The presentations will cover investigational medicines, established treatment formulations, patient preferences and research across different age groups. By examining clinical outcomes alongside everyday treatment experiences, the company aims to strengthen understanding of obesity management and the factors influencing long-term treatment engagement. ObesityWeek 2026 will provide an important scientific platform for researchers and healthcare professionals to examine these developments and discuss emerging approaches to obesity care. The findings may contribute to future clinical research and therapeutic development, although the investigational treatments and uses discussed will require appropriate clinical and regulatory assessment before approval.
Source: Novo Nordisk press release
